Société de Coordination de Recherches Thérapeutiques, 20220, Algajola, France.
Université Nice Sophia Antipolis, CNRS, Inserm, iBV, UFR de médecine Pasteur, 06107, Nice cedex 2, France.
J Trace Elem Med Biol. 2022 May;71:126931. doi: 10.1016/j.jtemb.2022.126931. Epub 2022 Jan 17.
Selective inhibitory effects of rhenium(I)-diselenoether (Re-diSe) were observed in cultured breast malignant cells. They were attributed to a decrease in Reactive Oxygen Species (ROS) production. A concomitant decrease in the production of Transforming Growth Factor-beta (TGFβ1), Insulin Growth Factor 1 (IGF1), and Vascular Endothelial Growth Factor A (VEGFA) by the malignant cells was also observed.
The study aimed to investigate the anti-tumor effects of Re-diSe on mice bearing 4T1 breast tumors, an experimental model of triple-negative breast cancer, and correlate them with several biomarkers.
4T1 mammary breast cancer cells were orthotopically inoculated into syngenic BALB/c Jack mice. Different doses of Re-diSe (1, 10, and 60 mg/kg) were administered orally for 23 consecutive days to assess the efficacy and toxicity. The oxidative status was evaluated by assaying Advanced Oxidative Protein Products (AOPP), and by the dinitrophenylhydrazone (DNPH) test in plasma of healthy mice, non-treated tumor-bearing mice (controls), treated tumor-bearing mice, and tumors in all tumor-bearing mice. Tumor necrosis factor (TNFα), VEGFA, VEGFB, TGFβ1, Interferon, and selenoprotein P (selenoP) were selected as biomarkers.
Doses of 1 and 10 mg/kg did not affect the tumor weights. There was a significant increase in the tumor weights in mice treated with the maximum dose of 60 mg/kg, concomitantly with a significant decrease in AOPP, TNFα, and TGFβ1 in the tumors. SelenoP concentrations increased in the plasma but not in the tumors.
We did not confirm the anti-tumor activity of the Re-diSe compound in this experiment. However, the transplantation of the tumor cells did not induce an expected pro-oxidative status without any increase of the oxidative biomarkers in the plasma of controls compared to healthy mice. This condition could be essential to evaluate the effect of an antioxidant drug. The choice of the experimental model will be primordial to assess the effects of the Re-diSe compound in further studies.
研究发现,铼(I)-二硒醚(Re-diSe)对培养的乳腺癌恶性细胞具有选择性抑制作用,这归因于活性氧(ROS)的产生减少。同时观察到恶性细胞产生的转化生长因子-β(TGFβ1)、胰岛素样生长因子 1(IGF1)和血管内皮生长因子 A(VEGFA)也减少。
本研究旨在探讨 Re-diSe 对 4T1 乳腺癌荷瘤小鼠的抗肿瘤作用,并与多种生物标志物相关联。
将 4T1 乳腺乳腺癌细胞原位接种于同基因 BALB/c Jack 小鼠。连续 23 天给予不同剂量的 Re-diSe(1、10 和 60mg/kg)口服,以评估疗效和毒性。通过测定健康小鼠、未经处理的荷瘤小鼠(对照组)、经处理的荷瘤小鼠和所有荷瘤小鼠肿瘤中的血浆中晚期氧化蛋白产物(AOPP)和二硝基苯肼(DNPH)试验来评估氧化状态。选择肿瘤坏死因子(TNFα)、VEGFA、VEGFB、TGFβ1、干扰素和硒蛋白 P(selenoP)作为生物标志物。
1mg/kg 和 10mg/kg 的剂量不影响肿瘤重量。用最大剂量 60mg/kg 处理的小鼠肿瘤重量显著增加,同时肿瘤中 AOPP、TNFα 和 TGFβ1 显著降低。血浆中 selenoP 浓度增加,但肿瘤中未增加。
在本实验中,我们未证实 Re-diSe 化合物的抗肿瘤活性。然而,与健康小鼠相比,肿瘤细胞的移植并未在对照组的血浆中引起预期的促氧化状态,也没有增加任何氧化生物标志物。这种情况对于评估抗氧化药物的作用至关重要。选择实验模型对于评估 Re-diSe 化合物在进一步研究中的作用至关重要。